



24 May 2023

SPP OFFER - ADDITIONAL INFORMATION FOR SUBSCRIBERS

Respiri Limited (ASX:RSH; OTCQB:RSHUF) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management, wishes to provide an update with respect to the non-underwritten SPP Offer to raise up to approximately A\$2 Million (before costs) (SPP Offer) that was announced by the Company on 23 May 2023.

As previously advised, under the SPP Offer, eligible shareholders (being those shareholders with a registered address in Australia and New Zealand as at 19 May 2023 (Record Date)) (Eligible Shareholders) will be entitled to subscribe for up to A\$30,000 in shares (SPP Shares) with 1 free-attaching Option for every 2 SPP Shares subscribed for under the SPP Offer. Eligible Shareholders may also be allowed to participate in a shortfall offer for any SPP Shares not subscribed for under the SPP Offer, at the Company’s discretion.

Additional Information:

To be eligible to receive the SPP Shares and free-attaching Option under the SPP Offer, Eligible Shareholders cannot sell their shares before the date that the SPP Offer has closed and will only be eligible to participate in the SPP Offer if they have not sold their shares before that closing date.

Further details about the SPP Offer will be set out in a prospectus (Prospectus), which Respiri expect to lodge on Tuesday, 30 May 2023. Eligible Shareholders will receive a copy of the Prospectus including a personalised offer letter and acceptance form which will provide further details of how to participate in the SPP Offer.

ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri’s innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri’s mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited’s operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co